Apeloa Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Apeloa Pharmaceutical Co Ltd (000739.CS)

Q3 202616 Jul – 14 Sep 2026

▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.
These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.
Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.
These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.
Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.
This is a new, significant negative financial result that directly impacts valuation and investor confidence.
CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.
This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

August 202616 Jul – 14 Sep 2026

▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.
These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.
Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.
These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.
Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.
This is a new, significant negative financial result that directly impacts valuation and investor confidence.
CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.
This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

Latest16 Jul – 14 Sep 2026

▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.
These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.
Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.
These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.
Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.
This is a new, significant negative financial result that directly impacts valuation and investor confidence.
CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.
This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.